Drug Trial Radar · NCT03035305
Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali
Last checked: Nov 20, 2026Latest source record: Jan 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36,717
Actual
Start
Aug 2016
Primary completion
Nov 2016
Study completion Nov 2016
Sponsor
- Lead sponsor
- Alliance for International Medical ActionAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France; Alliance médicale contre le paludisme, Mali; Programme National de Lutte contre le Paludisme, Niger; United States Agency for International Development (USAID); European Commission; Ministry of health, Mali
- First posted
- Jan 30, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 59 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SMC LNS Mali is a interventional matched-pair clustered cohort carried out between August and November 2017 in 18 health areas in Kolokani Circle, Koulikoro region, Mali. The objective of this study is to determine whether the association SMC and LNS reduces the number of confirmed malaria cases among children 6-59 months during the monthly SMC distribution sessions.
Conditions
- Malaria
Interventions
Lipid-based Nutrient Supplement (LNS)Dietary supplement
For each round of SMC distribution (total of 4 rounds): * For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks * For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks
Seasonal malaria chemopreventionDrug
For each round of SMC distribution (total of 4 rounds): * For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg * For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed malaria caseTime frame: From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Amcp/Alima
Kolokani Circle, Koulikoro, Mali
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.